The Impact of Donor Smoking on Primary Graft Dysfunction and Mortality after Lung Transplantation.

Primary graft dysfunction (PGD) is the leading cause of early morbidity and mortality after lung transplantation. Prior studies implicated proxy defined donor smoking as a risk factor for PGD and mortality. We aimed to more accurately assess the impact of donor smoke exposure on PGD and mortality using quantitative smoke exposure biomarkers. We performed a multicenter prospective cohort study of lung transplant recipients enrolled in the Lung Transplant Outcomes Group cohort between 2012-2018. PGD was defined as grade 3 at 48 or 72 hours after lung reperfusion. Donor smoking was defined utilizing accepted thresholds of urinary biomarkers of nicotine exposure (cotinine) and tobacco-specific nitrosamine (NNAL) in addition to clinical history. The donor smoking-PGD association was assessed using logistic regression and survival analysis was performed using inverse probability of exposure weighting according to smoking category. Active donor smoking prevalence varied by definition, with 34-43% based on urinary cotinine, 28% by urinary NNAL, and 37% by clinical documentation. The standardized risk of PGD associated with active donor smoking was higher across all definitions, with an absolute risk increase of 11·5% (95%CI 3·8, 19·2) by urinary cotinine, 5·7% (95%CI -3·4, 14·9) by urinary NNAL, and 6·5% (95%CI -2·8, 15·8) defined clinically. Donor smoking was not associated with differential post-lung transplant survival using any definition. Donor smoking associates with a modest increase in PGD risk but not with increased recipient mortality. Use of lungs from smokers is likely safe and may increase lung donor availability.